RDUS Live signals | Maximize Profits with Getagraph.com

SELL 157764 min ago

@ $24.14

Issued: 14 Feb 2024 @ 12:18

Return: -29.12%

Previous signal: Feb 12 - 15:20

Previous signal: Buy

Return: -4.60 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology...

Stats
Today's Volume	249 455
Average Volume	242 339
Market Cap	475.35M
EPS	$0 ( 2024-01-04 )
Next earnings date	( $-1.090 ) 2024-06-25
Last Dividend	$0.188 ( 2023-11-10 )
Next Dividend	$0 ( N/A )
P/E	-7.57
ATR14	$0.0260 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-06	Sutherlin Michael W	Buy	526	Class A Common Stock
2024-05-06	Shoemaker Leslie L	Buy	56	Class A Common Stock
2024-05-06	Minor Glenda J	Buy	123	Class A Common Stock
2024-05-06	Jahnke David L	Buy	667	Class A Common Stock
2024-05-06	Hunter Rhonda D	Buy	295	Class A Common Stock

INSIDER POWER
-81.34
Last 94 transactions
Buy: 7 094 100 \| Sell: 18 148 047

Volume Correlation

Long: -0.54 (weak negative)

Short: -0.87 (strong negative)

Signal:(45.459) Neutral

Radius Health Inc Correlation

10 Most Positive Correlations
ACON	0.957
ESCA	0.954
BPRN	0.953
WBD	0.949
AGRX	0.947
SSTI	0.947
TBLT	0.946
AUPH	0.946
APPS	0.946
RIVN	0.946

10 Most Negative Correlations
CDRO	-0.948
XOMA	-0.945
IBKR	-0.938
DXJS	-0.928
ESTA	-0.924
LPLA	-0.924
SHLD	-0.923
WING	-0.922
ACGL	-0.921
ADSE	-0.921

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Radius Health Inc Correlation - Currency/Commodity

0.41
( neutral )

0.37
( neutral )

0.00
( neutral )

0.32
( neutral )

-0.23
( neutral )

Radius Health Inc Financials

Annual	2023
Revenue:	$2.88B
Gross Profit:	$307.71M (10.68 %)
EPS:	$-0.920

FY	2023
Revenue:	$2.88B
Gross Profit:	$307.71M (10.68 %)
EPS:	$-0.920

FY	2022
Revenue:	$3.49B
Gross Profit:	$488.07M (14.00 %)
EPS:	$6.01

FY	2021
Revenue:	$229.97M
Gross Profit:	$210.82M (91.67 %)
EPS:	$-1.484

Financial Reports:

No articles found.

Radius Health Inc Dividends

(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0.188 (N/A)	$0.188 (N/A)	$0.188 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Radius Health Inc Dividend Information - Dividend Junior

Dividend Sustainability Score: 3.28 - low (9.11%) | Divividend Growth Potential Score: 0.555 - No dividend expected

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.188	2023-04-21
Last Dividend	$0.188	2023-11-10
Next Dividend	$0	N/A
Payout Date	2023-11-27
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	$0.563	--
Avg. Dividend % Per Year	0.60%	--
Score	2.34	--
Div. Sustainability Score	3.28
Div.Growth Potential Score	0.555
Div. Directional Score	1.915	--

Next Divdend (Est)
(2024-07-01)

$0.188 Estimate 22.50 %

Dividend Stability

0.60 Above Average

Dividend Score

2.34

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2023	$0.564	1.80%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Diamond	2023-12-14	Monthly	14	10.00%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
OXSQ	Dividend Royal	2023-12-14	Monthly	21	9.10%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
HRZN	Dividend Royal	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.00878	1.500	-0.176	-0.264	[0 - 0.5]
returnOnAssetsTTM	-0.0153	1.200	-0.511	-0.614	[0 - 0.3]
returnOnEquityTTM	-0.0285	1.500	-1.427	-2.14	[0.1 - 1]
payoutRatioTTM	-0.816	-1.000	-8.16	8.16	[0 - 1]
currentRatioTTM	1.755	0.800	6.23	4.98	[1 - 3]
quickRatioTTM	0.642	0.800	-0.931	-0.745	[0.8 - 2.5]
cashRatioTTM	0.0144	1.500	-1.031	-1.546	[0.2 - 2]
debtRatioTTM	0.236	-1.500	6.07	-9.11	[0 - 0.6]
interestCoverageTTM	-0.528	1.000	-1.307	-1.307	[3 - 30]
operatingCashFlowPerShareTTM	7.10	2.00	7.63	10.00	[0 - 30]
freeCashFlowPerShareTTM	3.31	2.00	8.34	10.00	[0 - 20]
debtEquityRatioTTM	0.453	-1.500	8.19	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.101	1.000	-1.651	-1.651	[0.2 - 0.8]
operatingProfitMarginTTM	-0.00359	1.000	-2.07	-2.07	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.502	1.000	8.32	8.32	[0.2 - 2]
assetTurnoverTTM	1.747	0.800	1.689	1.351	[0.5 - 2]
Total Score				3.28

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-18.59	1.000	-1.979	0	[1 - 100]
returnOnEquityTTM	-0.0285	2.50	-0.918	-2.14	[0.1 - 1.5]
freeCashFlowPerShareTTM	3.31	2.00	8.90	10.00	[0 - 30]
dividendYielPercentageTTM	4.38	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	7.10	2.00	7.63	10.00	[0 - 30]
payoutRatioTTM	-0.816	1.500	-8.16	8.16	[0 - 1]
pegRatioTTM	-0.437	1.500	-6.25	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0677	1.000	-0.807	0	[0.1 - 0.5]
Total Score				0.555

Radius Health Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Radius Health Inc

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.